Abstract
Objective: The etiological initiators of neuroinflammation remain inconclusive, and effective interventions to block neurodegeneration are unavailable. Surprisingly, we found collagen II-combined complete Freund’s adjuvant (CC) that usually induces rheumatoid arthritis (RA) also drives Alzheimer’s disease (AD)-like neurodegeneration in mice. CC not only upregulates the cerebral pro-inflammatory cytokines including tumor necrosis factor α (TNF-α) and interleukin 8 (IL-8), but also downregulates the cerebral interleukin 10 (IL-10), an anti-inflammatory cytokine, and tyrosine hydroxylase (TH), a ratelimiting enzyme for biosynthesis of the anti-inflammatory neurotransmitter dopamine. In contrast, electroacupuncture (EA) elevates TNF-α/IL-8 and declines IL-10/TH at first, but declines TNF-α/IL-8 and elevates IL-10/TH later. Upon impact on mitochondrial biogenesis, ubiquitination, and autophagy, EA firstly potentates but secondly attenuates CC-triggered signaling cascades leading to oxidation, nitrosylation, hypoxia, and angiogenesis. Eventually, EA compromises neurodegeneration by decreasing amyloid- β peptide (Aβ) and phosphorylated tau protein (p-tau), and also rectifies neuronal dysfunctions by increasing the cholinergic neurotransmitter acetylcholine (Ach) and its rate-limiting biosynthetic enzyme choline acetyltransferase (ChAT).
Results: Conclusively, EA initially aggravates and subsequently ameliorates CC-evoked AD-like earlyphase brain pathogenesis via conversion from pro-inflammatory microglia to anti-inflammatory microglia.Keywords: Alzheimer’s disease, electroacupuncture, inflammatory lesion, neuroinflammation, neurodegeneration, oxidative stress
[2]
Prince M, Wimo A, Guerchet M, Ali GC, Wu YT, Prina M, et al. World Alzheimer Report 2015. The Global Impact of Dementia.
An Analysis of Prevalence, Incidence, Cost and Trends (2015).
[3]
Alzheimer’s Association 2016 Alzheimer’s Disease Facts and Figures. Alzheimers Dement 12: 459-509. (2016).
[4]
Gatz M, Reynolds CA, Fratiglioni L, Johansson B, Mortimer JA, Berg S, et al. Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry 63: 168-74. (2006).
[5]
Bartus RT, Dean RL, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science 217: 408-17. (1982).
[6]
Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer’s disease. Trends Pharmacol Sci 12: 383-8. (1991).
[7]
Mudher A, Lovestone S. Alzheimer’s disease-do tauists and baptists finally shake hands? Trends Neurosci 25: 22-6. (2002).
[10]
Itzhaki RF, Lathe R, Balin BJ, Ball MJ, Bearer EL, Braak H, et al. Microbes and Alzheimer’s disease. J Alzheimers Dis 51: 979-84. (2016).
[11]
Soscia SJ, Kirby JE, Washicosky KJ, Tucker SM, Ingelsson M, Hyman B, et al. The Alzheimer’s disease-associated amyloid beta-protein is an antimicrobial peptide. PLoS One 5: e9505. (2010).
[12]
Alonso R, Pisa D, Marina AI, Morato E, Rabano A, Carrasco L. Fungal infection in patients with Alzheimer’s disease. J Alzheimers Dis 41: 301-11. (2014).
[13]
Pisa D, Alonso R, Rabano A, Rodal I, Carrasco L. Different brain regions are infected with fungi in Alzheimer’s disease. Sci Rep 5: 15015. (2015).
[14]
Bourgade K, Garneau H, Giroux G, Le Page AY, Bocti C, Dupuis G, et al. β-Amyloid peptides display protective activity against the human Alzheimer’s disease-associated herpes simplex virus-1. Biogerontology 16: 85-98. (2015).
[15]
McNamara J, Murray TA. Connections between herpes simplex virus type 1 and Alzheimer’s disease pathogenesis. Curr Alzheimer Res 13: 996-1005. (2016).
[16]
Noble JM, Scarmeas N, Celenti RS, Elkind MS, Wright CB, Schupf N, et al. Serum IgG antibody levels to periodontal microbiota are associated with incident Alzheimer’s disease. PLoS One 9: e114959. (2014).
[17]
Singhrao SK, Harding A, Poole S, Kesavalu L, Crean S. Porphyromonas gingivalis periodontal infection and its putative links with Alzheimer’s disease. Mediators Inflamm 2015: 137357. (2015).
[18]
Olsen I, Singhrao SK. Can oral infection be a risk factor for Alzheimer’s disease? J Oral Microbiol 7: 29143. (2015).
[19]
Webster SJ, Van Eldik LJ, Watterson DM, Bachstetter AD. Closed head injury in an age-related Alzheimer mouse model leads to an altered neuroinflammatory response and persistent cognitive impairment. J Neurosci 35: 6554-69. (2015).
[20]
Fiebich BL, Akter S, Akundi RS. The two-hit hypothesis for neuroinflammation: role of exogenous ATP in modulating inflammation in the brain. Front Cell Neurosci 8: 260. (2014).
[21]
Chin-Chan M, Navarro-Yepes J, Quintanilla-Vega B. Environmental pollutants as risk factors for neurodegenerative disorders: Alzheimer and Parkinson diseases. Front Cell Neurosci 9: 124. (2015).
[22]
Zhang R, Miller RG, Gascon R, Champion S, Katz J, Lancero M, et al. Circulating endotoxin and systemic immune activation in sporadic amyotrophic lateral sclerosis (sALS). J Neuroimmunol 206: 121-4. (2009).
[23]
Bao F, Wu P, Xiao N, Qiu F, Zeng QP. Nitric oxide-driven hypoxia initiates synovial angiogenesis, hyperplasia and inflammatory lesions in mice. PLoS One 7: e34494. (2012).
[24]
Gao Q, He J, Liao T, Zeng QP. 2,4-dinitrophenol downregulates genes for diabetes and fatty liver in obese mice. J Biosci Med 3: 44-51. (2015).
[25]
Kahn MS, Kranjac D, Alonzo CA, Haase JF, Cedillos RO, McLinden KA, et al. Prolonged elevation in hippocampal A beta and cognitive deficits following repeated endotoxin exposure in the mouse. Behav Brain Res 229: 176-84. (2012).
[26]
He Q, Yu W, Wu J, Chen C, Lou Z, Zhang Q, et al. Intranasal LPS-mediated Parkinson’s model challenges the pathogenesis of nasal cavity and environmental toxins. PLoS One 8: e78418. (2013).
[27]
Scheperjans F, Aho V, Pereira PA, Koskinen K, Paulin L, Pekkonen E, et al. Gut microbiota are related to Parkinson’s disease and clinical phenotype. Mov Disord 30: 350-8. (2015).
[28]
Szekely CA, Town T, Zandi PP. NSAIDs for the chemoprevention of Alzheimer’s disease. Subcell Biochem 42: 229-48. (2007).
[29]
Vegeto E, Benedusi V, Maggi A. Estrogen anti-inflammatory activity in brain: a therapeutic opportunity for menopause and neurodegenerative diseases. Front Neuroendocrinol 29: 507-19. (2008).
[30]
Spilman P, Podlutskaya N, Hart MJ, Debnath J, Gorostiza O, Bredesen D, et al. Inhibition of mTOR abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer’s disease. PLoS One 5: e9979. (2010).
[31]
Nerurkar PV, Johns LM, Buesa LM, Kipyakwai G, Volper E, Sato R, et al. Momordica charantia (bitter melon) attenuates high-fat diet-associated oxidative stress and neuroinflammation. J Neuroinflammation 8: 64. (2011).
[32]
Wang ZQ, Nie BB, Li DH, Zhao Z, Han Y, Song H, et al. Effect of acupuncture in mild cognitive impairment and Alzheimer’s disease: a functional MRI study. PLoS One 7: e42730. (2012).
[33]
Du YJ, Li RL, Sun GJ, Meng P, Song J. Pre-moxibustion and moxibustion prevent Alzheimer’s disease. Neural Regen Res 8: 2811-9. (2013).
[34]
Nam MH, Ahn KS, Choi SH. Acupuncture: a potent therapeutic tool for inducing adult neurogenesis. Neural Regen Res 10: 33-5. (2015).
[35]
Torres-Rosas R, Tehia G, Peña G, Mishra P, del Rocio Thompson-Bonilla M, Moreno-Eutimio MA, et al. Dopamine mediates vagal modulation of the immune system by electroacupuncture. Nat Med 20: 291-5. (2014).
[36]
Yiu EM, Chan KM, Li NY, Tsang R, Abbott KV, Kwong E, et al. Wound-healing effect of acupuncture for treating phonotraumatic vocal pathologies: A cytokine study. Laryngoscope 126: E18-22. (2016).
[37]
Kumar DK, Choi SH, Washicosky KJ, Eimer WA, Tucker S, et al. Amyloid-β peptide protects against microbial infection in mouse and worm models of Alzheimer’s disease. Sci Transl Med 8: 340ra72. (2016).
[38]
Carrettiero DC, Santiago FE, Motzko-Soares AC, Almeida MC. Temperature and toxic Tau in Alzheimer’s disease: new insights. Temperature (Austin) 2: 491-8. (2015).
[39]
Su B, Wang X, Lee HG, Tabaton M, Perry G, Smith MA, et al. Chronic oxidative stress causes increased tau phosphorylation in M17 neuroblastoma cells. Neurosci Lett 468: 267-71. (2010).
[40]
Ito D, Imai Y, Ohsawa K, Nakajima K, Fukuuchi Y, Kohsaka S. Microglia-specific localisation of a novel calcium binding protein, Iba1. Brain Res Mol Brain Res 57: 1-9. (1998).
[41]
Nazem A, Sankowski R, Bacher M, Al Abed Y. Rodent models of neuroinflammation for Alzheimer’s disease. J Neuroinflammation 12: 74. (2015).
[42]
Tang Y, Le WD. Differential roles of M1 and M2 microglia in neurodegenerative diseases. Mol Neurobiol 53: 1181-94. (2016).
[43]
Akhtar MW, Sanz Blasco S, Donatabadi N, Parker J, Chon K, Lee MS, et al. Elevated glucose and oligomeric β-amyloid disrupt synapses via a common pathway of aberrant protein S-nitrosylation. Nat Comms 7: 10242. (2016).
[44]
Serrano-Pozo A, Muzikansky A, Gómez-Isla T, Growdon JH, Betensky RA, Frosch MP, et al. Differential relationship of reactive astrocytes and microglia to fibrillar amyloid deposits in Alzheimer disease. J Neuropathol Exp Neurol 72: 462-71. (2013).
[45]
Levene YC, Li GK, Michel T. Agonist-modulated regulation of AMP-activated protein kinase in endothelial cells: evidence for an AMPK→Rac1→Akt→eNOS pathway. J Biol Chem 282: 20351-64. (2007).
[46]
Cassano T, Pace L, Bedse G, Lavecchia AM, De Marco F, Gaetani S, et al. Glutamate and mitochondria: two prominent players in the oxidative stress-induced neurodegeneration. Curr Alzheimer Res 13: 185-97. (2016).
[47]
Lee WJ, Kim M, Park HS, Kim HS, Jeon MJ, Oh KS, et al. AMPK activation increases fatty acid oxidation in skeletal muscle by activating PPAR alpha and PGC-1. Biochem Biophys Res Commun 340: 291-5. (2006).
[48]
Gusarove I, Nudler E. NO-mediated cytoprotection: instant adaptation to oxidative stress in bacteria. Proc Natl Acad Sci USA 102: 13855-60. (2005).
[49]
Jha MK, Park DH, Kook H, Lee IK, Lee WH, Suk K. Metabolic control of glia-mediated neuroinflammation. Curr Alzheimer Res 13: 387-402. (2016).
[50]
Springer MZ, Maceod DF. Mitophagy: mechanism and role in human disease. J Pathol 240: 253-5. (2016).
[51]
Pankiv S, Clausen TH, Lamark T, Brech A, Bruun JA, Outzen H, et al. p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy. J Biol Chem 282: 24131-45. (2007).
[52]
Zhong Y, Wang QJ, Li X, Yan Y, Backer JM, Chait BT, et al. Distinct regulation of autophagic activity by Atg14L and Rubicon associated with Beclin 1-phosphatidylinositol-3-kinase complex. Nat Cell Biol 11: 468-76. (2009).
[54]
Meijer AJ, Codogno P. AMP-activated protein kinase and autophagy. Autophagy 3: 238-340. (2007).
[55]
Arsham AM, Neufeld TP. Thinking globally and acting locally with TOR. Curr Opin Cell Biol 18: 589-97. (2006).
[56]
Wang DT, He J, Wu M, Li SM, Gao Q, Zeng QP. Artemisinin mimics calorie restriction to trigger mitochondrial biogenesis and compromise telomere shortening in mice. PeerJ 3: e822. (2015).
[57]
Osaka H, Wang YL, Takada K, Takizawa S, Setsuie R, Li H, et al. Ubiquitin carboxy-terminal hydrolase L1 binds to and stabilizes monoubiquitin in neuron. Hum Mol Genet 12: 1945-58. (2003).
[58]
Moudry P, Lukas C, Macurek L, Hanzlikova H, Hodny Z, Lukas J, et al. Ubiquitin-activating enzyme UBA1 is required for cellular response to DNA damage. Cell Cycle 11: 1573-82. (2012).
[59]
Leidecker O, Matic I, Mahata B, Pion E, Xirodimas DP. The ubiquitin E1 enzyme Ube1 mediates NEDD8 activation under diverse stress conditions. Cell Cycle 11: 1142-50. (2012).
Related Books
Frontiers in Clinical Drug Research - CNS and Neurological Disorders
Frontiers in Clinical Drug Research - CNS and Neurological Disorders
Frontiers in Clinical Drug Research - CNS and Neurological Disorders
Frontiers in Clinical Drug Research-Dementia
Frontiers in Clinical Drug Research - CNS and Neurological Disorders
Article Metrics
44
6